Giraffe Bio Raises $6.4M Seed to Squeeze More Copper From Old Mines

By Nathan Brooks

Giraffe Bio has raised a $6.4 million seed round to sell mines something they desperately need: a way to extract up to 5% more copper without sinking capital into a new pit. Orion Industrial Ventures led the round, with participation from BHP Ventures, Twynam, Air Capital and Baruch Future Ventures, TechCrunch has exclusively learned.

The timing explains the check sizes. By 2040, copper supplies could fall 25% short of demand, driven by the AI data center boom and economy-wide electrification. The mining industry's default answer — open new mines — is slow and statistically brutal: typically, just 0.3% of prospective mines pan out.

Giraffe Bio's answer is chemistry, tuned per deposit. The startup develops mineral-specific compounds that help mines recover up to 5% more copper. In mining, that amount "is really very material," Alejandro Buffo Sempé, co-founder and CEO of Giraffe Bio, told TechCrunch. Most operators, he noted, would be happy with an additional 1% to 2%.

How is Giraffe Bio different from the other biotech miners?

A wave of critical minerals startups — Endolith, Ceibo, Transition Metal Solutions — is already working the bio angle, mostly by focusing on heap leaches, where microbes help separate minerals from waste. Endolith has created "Olympic caliber" microbes, Ceibo is developing its own strains, and Transition Metal Solutions has built prebiotics to boost microbial activity.

Giraffe Bio splits from the pack on one point: it doesn't pour live bacteria onto the ore. Instead, it grows engineered microbes in a bioreactor and harvests the bespoke compounds they produce. Those chemicals then slot into a mine's existing process.

"We can leverage all of the biological machinery without having to deal with keeping alive a microbe, which is very complicated in [mining] environments," Buffo Sempé said.

That distinction matters for practitioners. Keeping microbes alive in a heap leach is an operational headache; a stable compound that drops into an existing flowsheet is a far easier sell to a mine manager.

What does this change for copper producers?

The compounds work in the flotation process, where chemicals push minerals to float or sink in a water bath so operators can skim the desirable ones off the top. Recovery rises the tighter the chemicals bind to the minerals of interest. "We are extremely good at only picking up the copper," Buffo Sempé said.

The same platform also targets the other half of the equation. Mines use chemicals called depressors to bind unwanted compounds like arsenic and sink them out of the mix, leaving more desirable products at the top. Giraffe Bio is developing biomolecule-based depressors too, the CEO said.

There's an environmental angle baked in. Flotation chemicals are often toxic, and Giraffe Bio says its biomolecules can replace them outright.

"Instead of pouring chemicals that are usually very harmful for the environment and so forth, we're replacing the function that they are providing to the flotation process with a biomolecule," Buffo Sempé said. "We're minimizing the friction towards maximizing the output."

Copper first, gold and silver next?

The startup is starting with copper, but the platform isn't married to it. Because the compounds are engineered to match each mine's mineral content, the company says the approach can be retargeted.

"The beauty of this is that we can target copper or we can target gold or silver," Buffo Sempé said.

With $6.4 million in the bank and BHP's venture arm on the cap table, Giraffe Bio now has to prove its lab-grown molecules hold up in operating plants. If a 5% recovery gain survives contact with real ore bodies, the addressable market is every copper mine already running.